Optimizing gelatin hydrogels for volumetric 3D bioprinting. Insights from Rousselot’s Jos Olijve on the ENLIGHT bioprinting ...

The TEDOPaM trial evaluating a novel maintenance therapy approach for advanced/metastatic pancreatic ductal adenocarcinoma has met its primary end point. The primary end point of 1-year overall ...

Centre for 3D models of Health and Disease, Division of Surgery and Interventional Science, University College London, London W1W 7TY, U.K. Centre for 3D models of Health and Disease, Division of ...

The model could help test the ability of different drugs in treating pancreatic cancer. Image credit: Shutterstock / Lightspring. A team of German scientists and biotech company Dynamic42 have jointly ...

The research, conducted in orthotopic models where human tumor cells grow in their natural pancreatic environment, showed that subcutaneously administered SIL204 significantly reduced primary ...

Silexion Therapeutics' Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic ...

Silexion Therapeutics’ Latest Data Demonstrates that Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models Where Human Pancreatic ...

Three-dimensional (3D) organoids are poised to be such a highly valuable system for a variety of gastrointestinal (GI) diseases. In the lab, organoids have emerged as powerful systems to model ...

AI-powered 3D object generators have revolutionized the way we create and visualize 3D models, making the process more efficient, accurate, and accessible to everyone. Whether you're a game developer, ...

Silexion Therapeutics Corp. has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. SIL-204 is a next-generation siRNA candidate designed to target a broad range of ...

Silexion Therapeutics completes initial study of SIL-204 in pancreatic cancer models, assessing tumor growth and metastasis. Results expected in March 2025. Silexion Therapeutics Corp. announced ...